secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2025-08-22T23:59:59+00:00
Accession:  0001193125-25-185553
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences doses first child in Phase 2 achondroplasia study of dabogratinib
--------------------------------------------------------------------------------

- First child dosed in BEACH301 Phase 2 study of dabogratinib (formerly TYRA-300) for achondroplasia.
- Initial results from safety sentinel cohort expected in second half of 2026.
- Dabogratinib is an FGFR3 inhibitor, Tyra's lead candidate for achondroplasia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000119312525185553/0001193125-25-185553-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000119312525185553/d15901d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-185553

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer